SCHEMBL12873545

SCHEMBL12873545

CC1CNC2CN(C)CC2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12457879 0.80
SCHEMBL2143600 0.80
SCHEMBL22249367 0.80
SCHEMBL14882767 0.71 CHRNB2 (0.31)
SCHEMBL22540549 0.71 CHRNB2 (0.31)
SCHEMBL24196772 0.71 CHRNB2 (0.31)
SCHEMBL22270766 0.71 CHRNB2 (0.31)
SCHEMBL20031391 0.71 CHRNB2 (0.31)
SCHEMBL19424165 0.71 CHRNB2 (0.31)
SCHEMBL11957184 0.71 CHRNB2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884099-B2 such as (R)-5'-[3-{1-(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy-benzoxazinorifamycin, useful as bactericides for the treatment of bacterial infections CUMBRE IP VENTURES, L.P. (US) 2011-02-08 US disclosed
WO-2009064792-A1 QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES CUMBRE PHARMACEUTICALS INC. (US) 2009-05-22 WO disclosed